ArticleScientific reports2025
Nematocidal activity of zinc oxide nanoparticles synthesized using chicken egg albumin in lung and spleen of Parascaris equorum experimentally infected rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Weight loss, weakness, coughing, nasal discharge, and neurological problems result from Parascaris equorum infection. However, severe infestations can cause intestinal impaction, colic, unthriftiness, peritonitis, and small intestine rupture, resulting in death. Parasite resistance to conventional drugs is mainly caused by decreased drug absorption and increased metabolism. Nanoparticle-based drugs can be viable alternatives. The study studied the pharmacological effects of zinc oxide nanoparticles( ZnO NPs) on P. equorum, infected rats' lungs and spleens. Thirty-six male rats were separated into two groups of 18 rats each: infected and uninfected. The two groups were divided into three subgroups that received orally distilled water, 30 mg/kg ZnO NPs, or 60 mg/kg for 10 days. Depending on dosage, ZnO NPs (30, 60 mg/kg) drastically reduced larvae in the lung and spleen. ZnO nanoparticles reduced malondialdehyde and nitric oxide and improved the antioxidant system in sick rats' spleens and lungs. The infected lung and spleen showed fewer histological changes after ZnO NPs (30, 60 mg/kg) therapy. Compared to rats infected but untreated, ZnO NPs at 30 and 60 mg/kg reduced nuclear factor-kappa B levels in immunohistochemistry. ZnO NPs do not harm animal cells and are harmless to non-infected rats. They can treat P. equorum infection due to their anthelmintic, antioxidant, healing, and anti-inflammatory properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.